1
|
Sepehri S, Saeedi M, Larijani B, Mahdavi M. Recent developments in the design and synthesis of benzylpyridinium salts: Mimicking donepezil hydrochloride in the treatment of Alzheimer's disease. Front Chem 2022; 10:936240. [PMID: 36226120 PMCID: PMC9549744 DOI: 10.3389/fchem.2022.936240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2022] [Accepted: 07/06/2022] [Indexed: 12/02/2022] Open
Abstract
Background: Alzheimer's disease (AD) is an advanced and irreversible degenerative disease of the brain, recognized as the key reason for dementia among elderly people. The disease is related to the reduced level of acetylcholine (ACh) in the brain that interferes with memory, learning, emotional, and behavior responses. Deficits in cholinergic neurotransmission are responsible for the creation and progression of numerous neurochemical and neurological illnesses such as AD. Aim: Herein, focusing on the fact that benzylpyridinium salts mimic the structure of donepezil hydrochlorideas a FDA-approved drug in the treatment of AD, their synthetic approaches and inhibitory activity against cholinesterases (ChEs) were discussed. Also, molecular docking results and structure-activity relationship (SAR) as the most significant concept in drug design and development were considered to introduce potential lead compounds. Key scientific concepts: AChE plays a chief role in the end of nerve impulse transmission at the cholinergic synapses. In this respect, the inhibition of AChE has been recognized as a key factor in the treatment of AD, Parkinson's disease, senile dementia, myasthenia gravis, and ataxia. A few drugs such as donepezil hydrochloride are prescribed for the improvement of cognitive dysfunction and memory loss caused by AD. Donepezil hydrochloride is a piperidine-containing compound, identified as a well-known member of the second generation of AChE inhibitors. It was established to treat AD when it was assumed that the disease is associated with a central cholinergic loss in the early 1980s. In this review, synthesis and anti-ChE activity of a library of benzylpyridinium salts were reported and discussed based on SAR studies looking for the most potent substituents and moieties, which are responsible for inducing the desired activity even more potent than donepezil. It was found that linking heterocyclic moieties to the benzylpyridinium salts leads to the potent ChE inhibitors. In this respect, this review focused on the recent reports on benzylpyridinium salts and addressed the structural features and SARs to get an in-depth understanding of the potential of this biologically improved scaffold in the drug discovery of AD.
Collapse
Affiliation(s)
- Saghi Sepehri
- Department of Medicinal Chemistry, School of Pharmacy, Ardabil University of Medical Sciences, Ardabil, Iran
- Pharmaceutical Sciences Research Center, Ardabil University of Medical Sciences, Ardabil, Iran
| | - Mina Saeedi
- Medicinal Plants Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
- Persian Medicine and Pharmacy Research Center, Tehran University of Medical Sciences, Tehran, Iran
| | - Bagher Larijani
- Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Mohammad Mahdavi
- Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
2
|
Lee HM, Andrys R, Jonczyk J, Kim K, Vishakantegowda AG, Malinak D, Skarka A, Schmidt M, Vaskova M, Latka K, Bajda M, Jung YS, Malawska B, Musilek K. Pyridinium-2-carbaldoximes with quinolinium carboxamide moiety are simultaneous reactivators of acetylcholinesterase and butyrylcholinesterase inhibited by nerve agent surrogates. J Enzyme Inhib Med Chem 2021; 36:437-449. [PMID: 33467931 PMCID: PMC7822067 DOI: 10.1080/14756366.2020.1869954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
The pyridinium-2-carbaldoximes with quinolinium carboxamide moiety were designed and synthesised as cholinesterase reactivators. The prepared compounds showed intermediate-to-high inhibition of both cholinesterases when compared to standard oximes. Their reactivation ability was evaluated in vitro on human recombinant acetylcholinesterase (hrAChE) and human recombinant butyrylcholinesterase (hrBChE) inhibited by nerve agent surrogates (NIMP, NEMP, and NEDPA) or paraoxon. In the reactivation screening, one compound was able to reactivate hrAChE inhibited by all used organophosphates and two novel compounds were able to reactivate NIMP/NEMP-hrBChE. The reactivation kinetics revealed compound 11 that proved to be excellent reactivator of paraoxon-hrAChE better to obidoxime and showed increased reactivation of NIMP/NEMP-hrBChE, although worse to obidoxime. The molecular interactions of studied reactivators were further identified by in silico calculations. Molecular modelling results revealed the importance of creation of the pre-reactivation complex that could lead to better reactivation of both cholinesterases together with reducing particular interactions for lower intrinsic inhibition by the oxime.
Collapse
Affiliation(s)
- Hyun Myung Lee
- Division of Bio and Drug Discovery, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.,Department of Medicinal Chemistry and Pharmacology, Daejeon, Republic of Korea
| | - Rudolf Andrys
- Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
| | - Jakub Jonczyk
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
| | - Kyuneun Kim
- Division of Bio and Drug Discovery, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.,Department of Medicinal Chemistry and Pharmacology, Daejeon, Republic of Korea
| | - Avinash G Vishakantegowda
- Division of Bio and Drug Discovery, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.,Department of Medicinal Chemistry and Pharmacology, Daejeon, Republic of Korea
| | - David Malinak
- Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
| | - Adam Skarka
- Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
| | - Monika Schmidt
- Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
| | - Michaela Vaskova
- Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
| | - Kamil Latka
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
| | - Marek Bajda
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
| | - Young-Sik Jung
- Division of Bio and Drug Discovery, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.,Department of Medicinal Chemistry and Pharmacology, Daejeon, Republic of Korea
| | - Barbara Malawska
- Department of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Krakow, Poland
| | - Kamil Musilek
- Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
| |
Collapse
|
3
|
Malinak D, Dolezal R, Hepnarova V, Hozova M, Andrys R, Bzonek P, Racakova V, Korabecny J, Gorecki L, Mezeiova E, Psotka M, Jun D, Kuca K, Musilek K. Synthesis, in vitro screening and molecular docking of isoquinolinium-5-carbaldoximes as acetylcholinesterase and butyrylcholinesterase reactivators. J Enzyme Inhib Med Chem 2020; 35:478-488. [PMID: 31910701 PMCID: PMC6968506 DOI: 10.1080/14756366.2019.1710501] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2019] [Revised: 12/19/2019] [Accepted: 12/24/2019] [Indexed: 11/15/2022] Open
Abstract
The series of symmetrical and unsymmetrical isoquinolinium-5-carbaldoximes was designed and prepared for cholinesterase reactivation purposes. The novel compounds were evaluated for intrinsic acetylcholinesterase (AChE) or butyrylcholinesterase (BChE) inhibition, when the majority of novel compounds resulted with high inhibition of both enzymes and only weak inhibitors were selected for reactivation experiments on human AChE or BChE inhibited by sarin, VX, or paraoxon. The AChE reactivation for all used organophosphates was found negligible if compared to the reactivation ability of obidoxime. Importantly, two compounds were found to reactivate BChE inhibited by sarin or VX better to obidoxime at human attainable concentration. One compound resulted as better reactivator of NEMP (VX surrogate)-inhibited BChE than obidoxime. The in vitro results were further rationalized by molecular docking studies showing future directions on designing potent BChE reactivators.
Collapse
Affiliation(s)
- David Malinak
- Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
- Biomedical Research Centre, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
| | - Rafael Dolezal
- Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
- Biomedical Research Centre, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
| | - Vendula Hepnarova
- Biomedical Research Centre, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic
| | - Miroslava Hozova
- Biomedical Research Centre, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
| | - Rudolf Andrys
- Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
| | - Petr Bzonek
- Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic
| | - Veronika Racakova
- Faculty of Informatics and Management, Center for Basic and Applied Research, University of Hradec Kralove, Hradec Kralove, Czech Republic
| | - Jan Korabecny
- Biomedical Research Centre, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic
| | - Lukas Gorecki
- Biomedical Research Centre, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
| | - Eva Mezeiova
- Biomedical Research Centre, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
| | - Miroslav Psotka
- Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
- Biomedical Research Centre, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
| | - Daniel Jun
- Biomedical Research Centre, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic
| | - Kamil Kuca
- Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
- Biomedical Research Centre, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
| | - Kamil Musilek
- Department of Chemistry, Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic
- Biomedical Research Centre, University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic
| |
Collapse
|
4
|
Vitamin B3-Based Biologically Active Compounds as Inhibitors of Human Cholinesterases. Int J Mol Sci 2020; 21:ijms21218088. [PMID: 33138280 PMCID: PMC7663184 DOI: 10.3390/ijms21218088] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Accepted: 10/27/2020] [Indexed: 12/21/2022] Open
Abstract
We evaluated the potential of nine vitamin B3 scaffold-based derivatives as acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors, as a starting point for the development of novel drugs for treating disorders with cholinergic neurotransmission-linked pathology. As the results indicate, all compounds reversibly inhibited both enzymes in the micromolar range pointing to the preference of AChE over BChE for binding the tested derivatives. Molecular docking studies revealed the importance of interactions with AChE active site residues Tyr337 and Tyr124, which dictated most of the observed differences. The most potent inhibitor of both enzymes with Ki of 4 μM for AChE and 8 μM for BChE was the nicotinamide derivative 1-(4′-phenylphenacyl)-3-carbamoylpyridinium bromide. Such a result places it within the range of several currently studied novel cholinesterase inhibitors. Cytotoxicity profiling did not classify this compound as highly toxic, but the induced effects on cells should not be neglected in any future detailed studies and when considering this scaffold for drug development.
Collapse
|
5
|
Bosak A, Ramić A, Šmidlehner T, Hrenar T, Primožič I, Kovarik Z. Design and evaluation of selective butyrylcholinesterase inhibitors based on Cinchona alkaloid scaffold. PLoS One 2018; 13:e0205193. [PMID: 30289893 PMCID: PMC6173406 DOI: 10.1371/journal.pone.0205193] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2018] [Accepted: 09/18/2018] [Indexed: 12/21/2022] Open
Abstract
This paper describes the synthesis and anticholinesterase potency of Cinchona-based alkaloids; ten quaternary derivatives of cinchonines and their corresponding pseudo-enantiomeric cinchonidines. The quaternization of quinuclidine moiety of each compound was carried out with groups diverse in their size: methyl, benzyl and differently meta- and para-substituted benzyl groups. All of the prepared compounds reversibly inhibited human butyrylcholinesterase and acetylcholinesterase with Ki constants within nanomolar to micromolar range. Five cinchonidine derivatives displayed 95-510 times higher inhibition selectivity to butyrylcholinesterase over acetylcholinesterase and four were potent butyrylcholinesterase inhibitors with Ki constants up to 100 nM, of which N-para-bromobenzyl cinchonidinium bromide can be considered a lead for further modifications and optimizations for possible use in the treatment of neurodegenerative diseases.
Collapse
Affiliation(s)
- Anita Bosak
- Institute for Medical Research and Occupational Health, Ksaverska cesta 2, Zagreb, Croatia
| | - Alma Ramić
- Faculty of Science, Horvatovac 102A, University of Zagreb, Zagreb, Croatia
| | - Tamara Šmidlehner
- Faculty of Science, Horvatovac 102A, University of Zagreb, Zagreb, Croatia
| | - Tomica Hrenar
- Faculty of Science, Horvatovac 102A, University of Zagreb, Zagreb, Croatia
| | - Ines Primožič
- Faculty of Science, Horvatovac 102A, University of Zagreb, Zagreb, Croatia
| | - Zrinka Kovarik
- Institute for Medical Research and Occupational Health, Ksaverska cesta 2, Zagreb, Croatia
| |
Collapse
|
6
|
Galdeano C, Coquelle N, Cieslikiewicz-Bouet M, Bartolini M, Pérez B, Clos MV, Silman I, Jean L, Colletier JP, Renard PY, Muñoz-Torrero D. Increasing Polarity in Tacrine and Huprine Derivatives: Potent Anticholinesterase Agents for the Treatment of Myasthenia Gravis. Molecules 2018. [PMID: 29534488 PMCID: PMC6017698 DOI: 10.3390/molecules23030634] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Symptomatic treatment of myasthenia gravis is based on the use of peripherally-acting acetylcholinesterase (AChE) inhibitors that, in some cases, must be discontinued due to the occurrence of a number of side-effects. Thus, new AChE inhibitors are being developed and investigated for their potential use against this disease. Here, we have explored two alternative approaches to get access to peripherally-acting AChE inhibitors as new agents against myasthenia gravis, by structural modification of the brain permeable anti-Alzheimer AChE inhibitors tacrine, 6-chlorotacrine, and huprine Y. Both quaternization upon methylation of the quinoline nitrogen atom, and tethering of a triazole ring, with, in some cases, the additional incorporation of a polyphenol-like moiety, result in more polar compounds with higher inhibitory activity against human AChE (up to 190-fold) and butyrylcholinesterase (up to 40-fold) than pyridostigmine, the standard drug for symptomatic treatment of myasthenia gravis. The novel compounds are furthermore devoid of brain permeability, thereby emerging as interesting leads against myasthenia gravis.
Collapse
Affiliation(s)
- Carles Galdeano
- Laboratory of Pharmaceutical Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain.
| | - Nicolas Coquelle
- Institut de Biologie Structurale, Université Grenoble Alpes, Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'Énergie Atomique (CEA) (UMR 5075), F-38054 Grenoble, France.
- Large-Scale Structures Group, Institut Laue-Langevin, 71 Avenue des Martyrs, 38000 Grenoble, France.
| | - Monika Cieslikiewicz-Bouet
- Laboratory COBRA (UMR 6014), Normandie Université, UNIROUEN, Institut National des Sciences Appliquées (INSA) Rouen, CNRS, 76000 Rouen, France.
| | - Manuela Bartolini
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Via Belmeloro 6, I-40126 Bologna, Italy.
| | - Belén Pérez
- Department of Pharmacology, Therapeutics and Toxicology, Neuroscience Institute, Autonomous University of Barcelona, E-08193 Barcelona, Spain.
| | - M Victòria Clos
- Department of Pharmacology, Therapeutics and Toxicology, Neuroscience Institute, Autonomous University of Barcelona, E-08193 Barcelona, Spain.
| | - Israel Silman
- Department of Neurobiology, Weizmann Institute of Science, 76100 Rehovot, Israel.
| | - Ludovic Jean
- Laboratory COBRA (UMR 6014), Normandie Université, UNIROUEN, Institut National des Sciences Appliquées (INSA) Rouen, CNRS, 76000 Rouen, France.
| | - Jacques-Philippe Colletier
- Institut de Biologie Structurale, Université Grenoble Alpes, Centre National de la Recherche Scientifique (CNRS)-Commissariat à l'Énergie Atomique (CEA) (UMR 5075), F-38054 Grenoble, France.
| | - Pierre-Yves Renard
- Laboratory COBRA (UMR 6014), Normandie Université, UNIROUEN, Institut National des Sciences Appliquées (INSA) Rouen, CNRS, 76000 Rouen, France.
| | - Diego Muñoz-Torrero
- Laboratory of Pharmaceutical Chemistry (CSIC Associated Unit), Faculty of Pharmacy and Food Sciences, and Institute of Biomedicine (IBUB), University of Barcelona, Av. Joan XXIII 27-31, E-08028 Barcelona, Spain.
| |
Collapse
|
7
|
Kuca K, Karasova JZ, Soukup O, Kassa J, Novotna E, Sepsova V, Horova A, Pejchal J, Hrabinova M, Vodakova E, Jun D, Nepovimova E, Valis M, Musilek K. Development of small bisquaternary cholinesterase inhibitors as drugs for pre-treatment of nerve agent poisonings. DRUG DESIGN DEVELOPMENT AND THERAPY 2018; 12:505-512. [PMID: 29563775 PMCID: PMC5849933 DOI: 10.2147/dddt.s133038] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Background Intoxication by nerve agents could be prevented by using small acetylcholinesterase inhibitors (eg, pyridostigmine) for potentially exposed personnel. However, the serious side effects of currently used drugs led to research of novel potent molecules for prophylaxis of organophosphorus intoxication. Methods The molecular design, molecular docking, chemical synthesis, in vitro methods (enzyme inhibition, cytotoxicity, and nicotinic receptors modulation), and in vivo methods (acute toxicity and prophylactic effect) were used to study bispyridinium, bisquinolinium, bisisoquinolinium, and pyridinium-quinolinium/isoquinolinium molecules presented in this study. Results The studied molecules showed non-competitive inhibitory ability towards human acetylcholinesterase in vitro that was further confirmed by molecular modelling studies. Several compounds were selected for further studies. First, their cytotoxicity, nicotinic receptors modulation, and acute toxicity (lethal dose for 50% of laboratory animals [LD50]; mice and rats) were tested to evaluate their safety with promising results. Furthermore, their blood levels were measured to select the appropriate time for prophylactic administration. Finally, the protective ratio of selected compounds against soman-induced toxicity was determined when selected compounds were found similarly potent or only slightly better to standard pyridostigmine. Conclusion The presented small bisquaternary molecules did not show overall benefit in prophylaxis of soman-induced in vivo toxicity.
Collapse
Affiliation(s)
- Kamil Kuca
- Department of Chemistry, Faculty of Science, University of Hradec Kralove.,Biomedical Research Center, University Hospital Hradec Kralove
| | - Jana Zdarova Karasova
- Biomedical Research Center, University Hospital Hradec Kralove.,Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence
| | - Ondrej Soukup
- Biomedical Research Center, University Hospital Hradec Kralove
| | - Jiri Kassa
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence
| | - Eva Novotna
- Biomedical Research Center, University Hospital Hradec Kralove
| | - Vendula Sepsova
- Biomedical Research Center, University Hospital Hradec Kralove.,Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence
| | - Anna Horova
- Biomedical Research Center, University Hospital Hradec Kralove
| | - Jaroslav Pejchal
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence
| | - Martina Hrabinova
- Biomedical Research Center, University Hospital Hradec Kralove.,Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence
| | - Eva Vodakova
- Biomedical Research Center, University Hospital Hradec Kralove
| | - Daniel Jun
- Biomedical Research Center, University Hospital Hradec Kralove.,Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence
| | - Eugenie Nepovimova
- Department of Chemistry, Faculty of Science, University of Hradec Kralove.,Biomedical Research Center, University Hospital Hradec Kralove
| | - Martin Valis
- Department of Neurology, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Kamil Musilek
- Department of Chemistry, Faculty of Science, University of Hradec Kralove.,Biomedical Research Center, University Hospital Hradec Kralove
| |
Collapse
|
8
|
Shchepina NE, Avrorin VV, Badun GA, Shurov SN, Shchepin RV. Nuclear-chemical synthesis of tritium-labeled fluorinated isoquinolinium derivatives. RADIOCHEMISTRY 2017. [DOI: 10.1134/s1066362217030134] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
9
|
Soukup O, Winder M, Killi UK, Wsol V, Jun D, Kuca K, Tobin G. Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment. Curr Neuropharmacol 2017; 15:637-653. [PMID: 27281175 PMCID: PMC5543679 DOI: 10.2174/1570159x14666160607212615] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2016] [Revised: 04/28/2016] [Accepted: 05/31/2016] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND Pharmaceuticals with targets in the cholinergic transmission have been used for decades and are still fundamental treatments in many diseases and conditions today. Both the transmission and the effects of the somatomotoric and the parasympathetic nervous systems may be targeted by such treatments. Irrespective of the knowledge that the effects of neuronal signalling in the nervous systems may include a number of different receptor subtypes of both the nicotinic and the muscarinic receptors, this complexity is generally overlooked when assessing the mechanisms of action of pharmaceuticals. METHODS We have search of bibliographic databases for peer-reviewed research literature focused on the cholinergic system. Also, we have taken advantage of our expertise in this field to deduce the conclusions of this study. RESULTS Presently, the life cycle of acetylcholine, muscarinic receptors and their effects are reviewed in the major organ systems of the body. Neuronal and non-neuronal sources of acetylcholine are elucidated. Examples of pharmaceuticals, in particular cholinesterase inhibitors, affecting these systems are discussed. The review focuses on salivary glands, the respiratory tract and the lower urinary tract, since the complexity of the interplay of different muscarinic receptor subtypes is of significance for physiological, pharmacological and toxicological effects in these organs. CONCLUSION Most pharmaceuticals targeting muscarinic receptors are employed at such large doses that no selectivity can be expected. However, some differences in the adverse effect profile of muscarinic antagonists may still be explained by the variation of expression of muscarinic receptor subtypes in different organs. However, a complex pattern of interactions between muscarinic receptor subtypes occurs and needs to be considered when searching for selective pharmaceuticals. In the development of new entities for the treatment of for instance pesticide intoxication, the muscarinic receptor selectivity needs to be considered. Reactivators generally have a muscarinic M2 receptor acting profile. Such a blockade may engrave the situation since it may enlarge the effect of the muscarinic M3 receptor effect. This may explain why respiratory arrest is the major cause for deaths by esterase blocking.
Collapse
Affiliation(s)
- Ondrej Soukup
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic
| | - Michael Winder
- Institute of Neuroscience and Physiology, Department of Pharmacology, the Sahlgrenska Academy at the University of Gothenburg, Sweden
| | - Uday Kumar Killi
- Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic
| | - Vladimir Wsol
- Department of Biochemical Sciences, Faculty of Pharmacy, Charles University, Hradec Kralove, Czech Republic
| | - Daniel Jun
- Biomedical Research Centre, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic
| | - Kamil Kuca
- Biomedical Research Centre, University Hospital Hradec Kralove, Czech Republic
| | - Gunnar Tobin
- Institute of Neuroscience and Physiology, Department of Pharmacology, the Sahlgrenska Academy at the University of Gothenburg, Sweden
| |
Collapse
|
10
|
Hrabcova V, Korabecny J, Manyova B, Matouskova L, Kucera T, Dolezal R, Musilek K, Gorecki L, Nepovimova E, Kuca K, Jun D. Bis-isoquinolinium and bis-pyridinium acetylcholinesterase inhibitors: in vitro screening of probes for novel selective insecticides. RSC Adv 2017. [DOI: 10.1039/c7ra05838a] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
Library screening of pyridinium-based compounds, acting as acetylcholinesterase inhibitors, for their potential insecticidal efficacy.
Collapse
|
11
|
QSAR modeling of bis-quinolinium and bis-isoquinolinium compounds as acetylcholine esterase inhibitors based on the Monte Carlo method—the implication for Myasthenia gravis treatment. Med Chem Res 2016. [DOI: 10.1007/s00044-016-1720-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Karasova JZ, Hroch M, Musilek K, Kuca K. Small Quaternary Inhibitors K298 and K524: Cholinesterases Inhibition, Absorption, Brain Distribution, and Toxicity. Neurotox Res 2015; 29:267-74. [DOI: 10.1007/s12640-015-9582-4] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2015] [Revised: 11/06/2015] [Accepted: 11/24/2015] [Indexed: 10/22/2022]
|
13
|
Santillo MF, Liu Y. A fluorescence assay for measuring acetylcholinesterase activity in rat blood and a human neuroblastoma cell line (SH-SY5Y). J Pharmacol Toxicol Methods 2015; 76:15-22. [DOI: 10.1016/j.vascn.2015.07.002] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2015] [Revised: 07/02/2015] [Accepted: 07/06/2015] [Indexed: 11/15/2022]
|
14
|
Mic M, Pîrnău A, Neamţu S, Palage M, Bogdan M. Molecular interaction of β-CD with 3-carboxy-1-[(2-phenyl-1,3-thiazol-4-yl) methyl]pyridin-1-ium iodide analyzed by isothermal titration calorimetry and NMR spectroscopy. J INCL PHENOM MACRO 2015. [DOI: 10.1007/s10847-015-0561-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
15
|
Singh N, Karpichev Y, Tiwari AK, Kuca K, Ghosh KK. Oxime functionality in surfactant self-assembly: An overview on combating toxicity of organophosphates. J Mol Liq 2015. [DOI: 10.1016/j.molliq.2015.04.010] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
16
|
Koca M, Yerdelen KO, Anil B, Kasap Z. Microwave-Assisted Synthesis, Molecular Docking, and Cholinesterase Inhibitory Activities of New Ethanediamide and 2-Butenediamide Analogues. Chem Pharm Bull (Tokyo) 2015; 63:210-7. [DOI: 10.1248/cpb.c14-00754] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Mehmet Koca
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ataturk University
| | | | - Baris Anil
- Department of Organic Chemistry, Faculty of Science, Ataturk University
| | - Zeynep Kasap
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ataturk University
| |
Collapse
|
17
|
Yerdelen KO, Koca M, Kasap Z, Anil B. Preparation, anticholinesterase activity, and docking study of new 2-butenediamide and oxalamide derivatives. J Enzyme Inhib Med Chem 2014; 30:671-8. [PMID: 25431144 DOI: 10.3109/14756366.2014.959947] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Several new oxalamide and 2-butenediamide derivatives have been designed, synthesized and evaluated as the acetyl- and butyryl-cholinesterase inhibitors for Alzheimer's disease. The enzyme inhibitory activity of the synthesized compounds was measured using Ellman's colorimetric method. It was revealed that compound 1a (N,N'-bis-(4-chloro-benzyl)-N,N'-diphenyl-oxalamide) showed maximum activity against BuChE with a half maximal inhibitory concentration (IC50) = 1.86 µM and compound 2a (but-2-enedioic acid bis-[(4-chloro-benzyl)-phenyl-amide]) exhibited optimum AChE (IC50 = 1.51 µM) inhibition with a high-selectivity index. To better understand the enzyme-inhibitor interaction of the most active compounds towards cholinesterase, molecular modelling studies were carried out. Docking simulations revealed that inhibitors 1a and 2a targeted both the catalytic active site and the peripheral anionic site of 1ACJ and 1P0I.
Collapse
|
18
|
Sepsova V, Krusek J, Zdarova Karasova J, Zemek F, Musilek K, Kuca K, Soukup O. The interaction of quaternary reversible acetylcholinesterase inhibitors with the nicotinic receptor. Physiol Res 2014; 63:771-7. [PMID: 25157661 DOI: 10.33549/physiolres.932768] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Acetylcholinesterase inhibitors (AChEIs) are used in the treatment of myasthenia gravis (MG). We investigated the effects of AChEIs on peripheral nicotinic receptors (nAChR), which play a crucial role in the treatment of MG symptoms. The positive modulation of those receptors by AChE inhibitors could have an added value to the anti-AChE activity and might be useful in the therapy of MG. Furthermore, to estimate the potential drawbacks of the compounds, cytotoxicity has been assessed on various cell lines. The whole-cell mode of the patch-clamp method was employed. The experiments were performed on medulloblastoma/rhabdomyosarcoma cell line TE671 expressing human embryonic muscle-like receptor with subunits alpha2betagammadelta. The effect of the compounds on cell viability was measured by standard MTT assay (Sigma Aldrich) on ACHN (renal cell adenocarcinoma), HeLa (immortal cell line derived from a cervical carcinoma), HEPG2 (hepatocellular carcinoma) and BJ (skin fibroblasts) cell lines. No positive modulation by the tested AChE inhibitors was observed. Moreover, the compounds exhibited antagonistic activity on the peripheral nAChR. Standard drugs used in MG treatment were shown to be less potent inhibitors of muscle-type nAChR than the newly synthesized compounds. The new compounds showed very little effect on cell viability, and toxicities were comparable to standards. Newly synthesized AChEIs inhibited peripheral nAChR. Furthermore, the inhibition was higher than that of standards used for the treatment of MG. They could be used for the study of nAChR function, thanks to their high antagonizing potency and fast recovery of receptor activity after their removal. However, since no positive modulation was observed, the new compounds do not seem to be promising candidates for MG treatment, even though their cytotoxic effect was relatively low.
Collapse
Affiliation(s)
- V Sepsova
- Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Hradec Kralove, Czech Republic, Biomedical Research Center, Hradec Kralove, Czech Republic.
| | | | | | | | | | | | | |
Collapse
|
19
|
Yerdelen KO, Tosun E. Synthesis, docking and biological evaluation of oxamide and fumaramide analogs as potential AChE and BuChE inhibitors. Med Chem Res 2014. [DOI: 10.1007/s00044-014-1152-4] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
20
|
Komloova M, Horova A, Hrabinova M, Jun D, Dolezal M, Vinsova J, Kuca K, Musilek K. Preparation, in vitro evaluation and molecular modelling of pyridinium–quinolinium/isoquinolinium non-symmetrical bisquaternary cholinesterase inhibitors. Bioorg Med Chem Lett 2013; 23:6663-6. [DOI: 10.1016/j.bmcl.2013.10.043] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2013] [Revised: 10/19/2013] [Accepted: 10/22/2013] [Indexed: 10/26/2022]
|
21
|
Janockova J, Gulasova Z, Musilek K, Kuca K, Kozurkova M. Novel cholinesterase modulators and their ability to interact with DNA. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2013; 115:364-369. [PMID: 23851179 DOI: 10.1016/j.saa.2013.06.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/26/2013] [Revised: 05/23/2013] [Accepted: 06/04/2013] [Indexed: 06/02/2023]
Abstract
In the present work, an interaction of four cholinesterase modulators (1-4) with calf thymus DNA was studied via spectroscopic techniques (UV-Vis, fluorescent spectroscopy and circular dichroism). From UV-Vis spectroscopic analysis, the binding constants for DNA-pyridinium oximes complexes were calculated (K=3.5×10(4) to 1.4×10(5)M(-1)). All these measurements indicated that the compounds behave as effective DNA-interacting agents. Electrophoretic techniques proved that ligand 2 inhibited topoisomerase I at a concentration 5μM.
Collapse
Affiliation(s)
- Jana Janockova
- Institute of Chemistry, Department of Biochemistry, P.J. Šafárik University, Faculty of Science, Moyzesova 11, 04001 Kosice, Slovak Republic
| | | | | | | | | |
Collapse
|
22
|
Kwok JC, Macartney DH. Cucurbit[7]uril complexations of bis(isoquinolinium)alkane dications in aqueous solution. Supramol Chem 2013. [DOI: 10.1080/10610278.2013.842645] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Julian C. Kwok
- Department of Chemistry, Queen's University, 90 Bader Lane, Kingston, ON, Canada K7L 4K8
| | - Donal H. Macartney
- Department of Chemistry, Queen's University, 90 Bader Lane, Kingston, ON, Canada K7L 4K8
| |
Collapse
|
23
|
Sepsova V, Karasova JZ, Korabecny J, Dolezal R, Zemek F, Bennion BJ, Kuca K. Oximes: inhibitors of human recombinant acetylcholinesterase. A structure-activity relationship (SAR) study. Int J Mol Sci 2013; 14:16882-900. [PMID: 23959117 PMCID: PMC3759941 DOI: 10.3390/ijms140816882] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2013] [Revised: 08/01/2013] [Accepted: 08/02/2013] [Indexed: 11/16/2022] Open
Abstract
Acetylcholinesterase (AChE) reactivators were developed for the treatment of organophosphate intoxication. Standard care involves the use of anticonvulsants (e.g., diazepam), parasympatolytics (e.g., atropine) and oximes that restore AChE activity. However, oximes also bind to the active site of AChE, simultaneously acting as reversible inhibitors. The goal of the present study is to determine how oxime structure influences the inhibition of human recombinant AChE (hrAChE). Therefore, 24 structurally different oximes were tested and the results compared to the previous eel AChE (EeAChE) experiments. Structural factors that were tested included the number of pyridinium rings, the length and structural features of the linker, and the number and position of the oxime group on the pyridinium ring.
Collapse
Affiliation(s)
- Vendula Sepsova
- Department of Toxicology, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic; E-Mails: (V.S.); (J.K.); (F.Z.)
| | - Jana Zdarova Karasova
- Department of Public Health, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic; E-Mail:
- University Hospital, Biomedicinal Research Centre, Sokolska 581, 50005 Hradec Kralove, Czech Republic; E-Mail:
| | - Jan Korabecny
- Department of Toxicology, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic; E-Mails: (V.S.); (J.K.); (F.Z.)
- University Hospital, Biomedicinal Research Centre, Sokolska 581, 50005 Hradec Kralove, Czech Republic; E-Mail:
| | - Rafael Dolezal
- University Hospital, Biomedicinal Research Centre, Sokolska 581, 50005 Hradec Kralove, Czech Republic; E-Mail:
| | - Filip Zemek
- Department of Toxicology, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic; E-Mails: (V.S.); (J.K.); (F.Z.)
| | - Brian J. Bennion
- Biosciences and Biotechnology Division, Lawrence Livermore National Laboratory, 7000 East Ave, Livermore, CA 94550, USA; E-Mail:
| | - Kamil Kuca
- University Hospital, Biomedicinal Research Centre, Sokolska 581, 50005 Hradec Kralove, Czech Republic; E-Mail:
- Center of Advances Studies, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic
| |
Collapse
|
24
|
Korochkina MG, Nikitashina AD, Khaybullin RN, Petrov KA, Strobykina IY, Zobov VV, Kataev VE. Unfolded and macrocyclic ammonium derivatives of diterpenoids steviol and isosteviol having choline moieties. Synthesis and inhibitory activities toward acetylcholine- and butyrylcholinesterases. MEDCHEMCOMM 2012. [DOI: 10.1039/c2md20165h] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Derivatives of isosteviol and steviol possessing choline moieties have been synthesized and assayed for AchE and BchE inhibitory activity.
Collapse
Affiliation(s)
- Mayya G. Korochkina
- A.E. Arbuzov Institute of Organic and Physical Chemistry
- Russian Academy of Sciences
- Kazan
- Russian Federation
| | - Alexandra D. Nikitashina
- A.E. Arbuzov Institute of Organic and Physical Chemistry
- Russian Academy of Sciences
- Kazan
- Russian Federation
| | - Ravil N. Khaybullin
- A.E. Arbuzov Institute of Organic and Physical Chemistry
- Russian Academy of Sciences
- Kazan
- Russian Federation
| | - Konstantin A. Petrov
- A.E. Arbuzov Institute of Organic and Physical Chemistry
- Russian Academy of Sciences
- Kazan
- Russian Federation
| | - Irina Yu. Strobykina
- A.E. Arbuzov Institute of Organic and Physical Chemistry
- Russian Academy of Sciences
- Kazan
- Russian Federation
| | - Vladimir V. Zobov
- A.E. Arbuzov Institute of Organic and Physical Chemistry
- Russian Academy of Sciences
- Kazan
- Russian Federation
| | - Vladimir E. Kataev
- A.E. Arbuzov Institute of Organic and Physical Chemistry
- Russian Academy of Sciences
- Kazan
- Russian Federation
| |
Collapse
|
25
|
Kassa J, Musilek K, Koomlova M, Bajgar J. A Comparison of the Efficacy of Newly Developed Reversible Inhibitors of Acetylcholinesterase with Commonly Used Pyridostigmine as Pharmacological Pre-Treatment of Soman-Poisoned Mice. Basic Clin Pharmacol Toxicol 2011; 110:322-6. [DOI: 10.1111/j.1742-7843.2011.00808.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Komloova M, Musilek K, Horova A, Holas O, Dohnal V, Gunn-Moore F, Kuca K. Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment. Bioorg Med Chem Lett 2011; 21:2505-9. [PMID: 21397501 DOI: 10.1016/j.bmcl.2011.02.047] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2011] [Revised: 02/10/2011] [Accepted: 02/12/2011] [Indexed: 11/24/2022]
Abstract
This paper describes the preparation and in vitro evaluation of 18 newly prepared bis-quinolinium inhibitors on human recombinant acetylcholinesterase (AChE) and human plasmatic butyrylcholinesterase (BChE). Their inhibitory (IC(50)) and was compared to the chosen standards ambenonium dichloride, edrophonium chloride, BW284c51 and ethopropazine hydrochloride. One novel compound was found to be a promising inhibitor of hAChE (in nM range) and was better than edrophonium chloride or BW284c51, but was worse than ambenonium chloride. This compound also showed selectivity towards hAChE and it was confirmed as a non-competitive inhibitor of hAChE by kinetic analysis. A molecular modelling study further confirmed its binding to the peripheral active site of hAChE via apparent π-π or π-cationic interactions.
Collapse
Affiliation(s)
- Marketa Komloova
- Charles University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry and Drug Control, Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic
| | | | | | | | | | | | | |
Collapse
|